This post was originally published on this site Alzheimer’s disease patients carrying a gene found only in humans, called CHRFAM7A, are less responsive to cholinesterase inhibitors, a new study reports. These findings may explain why some therapeutic benefits seen in animal studies have failed to translate to patients. Kinga Szigeti, MD, PhD, director of the…
This post was originally published on this site Nearly $169,000 was raised to support the Leukemia & Lymphoma Society’s research, legislative advocacy, and patient support efforts by one of its chapter’s Man & Woman of the Year campaign. California residents Nancy Whitman and John Romley won the title for the Silicon Valley & Monterey Bay…
This post was originally published on this site A first-in-human Phase 1 clinical trial has been launched to assess the effects of NantKwest’s investigational PD-L1 t-haNK cell therapy in patients with locally advanced or metastatic solid cancers. The authorization to start the trial came after the U.S. Food and Drug Administration (FDA) completed a review…
This post was originally published on this site Minerva Biotechnologies will soon start the first human trials testing its investigational therapy huMNC2-CAR44, a CAR T-cell immunotherapy intended for breast cancer that has spread to other parts of the body. The announcement comes after the U.S. Food and Drug Administration (FDA) approved the company’s investigational new…
This post was originally published on this site Following the approval of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), Samus Therapeutics is launching a Phase 1 trial in the United States to evaluate the safety of its investigational therapy PU-AD, an epichaperome inhibitor, for the treatment of Alzheimer’s…
This post was originally published on this site Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a way to improve the treatment decision process for ovarian cancer. Despite the advances made to improve diagnosis…
This post was originally published on this site To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to establish a “gold standard” immune profiling platform for multiple myeloma research studies, and to produce the kind of…
This post was originally published on this site Triumvira Immunulogics is launching a Phase 1/2 clinical trial to test its T-cell therapy candidate, TAC01-CD19, in patients with B-cell lymphoma across the U.S. and Canada, the company announced. The TACTIC-19 trial (NCT03880279), set to begin in a few months, comes after the U.S Food and Drug…
This post was originally published on this site PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a second generation fluorine-labeled small molecule that…
This post was originally published on this site Syntrix Pharmaceuticals has dosed the first patient in an ongoing Phase 1/2 clinical trial testing its experimental therapy SX-682 in combination with Keytruda (pembrolizumab) as a treatment for advanced melanoma, the company announced. The open-label trial (NCT03161431) is being conducted at the Massachusetts General Hospital Cancer Center and…
